Brief: Arocell Presents Results From The U-CAN TK1 Lymphoma Study

IDL Diagnostics AB (publ)

27/11/2018 14:02

Nov 27 (Reuters) - AroCell AB (publ)  AROC.ST :
    * REG-AROCELL PRESENTS RESULTS FROM THE U-CAN TK1 LYMPHOMA
STUDY
AND FROM A COMPARISON STUDY BETWEEN TK 210™ ELISA AND OTHER
ASSAYS
    * RESULTS SUGGEST THAT TK 210 ELISA MAY BE USED FOR
MONITORING
EFFECT OF THERAPY OF DLBCL PATIENTS UNDER RITUXIMAB + CHOP
TREATMENT
    * STUDY ALSO SHOWS THAT AROCELL'S UNIQUE SAMPLE DILUTION
BUFFER
CONTRIBUTES TO IMPROVE DIAGNOSTIC PERFORMANCE
    * RESULTS SHOW THAT TK 210 ELISA HAS SIMILAR PERFORMANCE
COMPARED
TO LIAISON THYMIDINE KINASE AND (3)H-DTHD PHOSPHORYLATION ASSAY

Source text for Eikon:  ID:nGNE1YPSGF 
Further company coverage:  AROC.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))